GDC 0068, NVP-BKM120, GSK 2141795, MK2206, perifosine A-443654, and GSK690693 are AKT inhibitors that have shown significant antitumor effects in LC patients [36]. Here, AKT1 is linked to laryngotracheoesophageal cleft.